About this policy
Minor revision to existing policy, L34338 Transthoracic Echocardiography (TTE) - added Section on CAMZYOS™ (mavacamten) treatment which is for symptomatic obstructive hypertrophic cardiomyopathy NYHA Class II-III and can only be used as part of the CAMZYOS Risk Evaluation and Mitigation Strategy (REMS) program. This policy will be in notice April 13, 2023 thru May 27, 2023, becoming effective May 28, 2023.
Codes in this policy
Code numbers and each code’s status as the policy records it. CPT code descriptions are left out of this page, as are the passages that cite CPT codes; the official document has them.
Backwork has no codes on record for this policy. Check the source.